* Ultralife Corp ULBI.OQ ULBI.O is expected to report
results on February 3.
* The Newark New York New York-based company is expected to
report revenue of $21 million, according to the estimate from
one analyst, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Ultralife Corp is
for a
loss of 4 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Ultralife
Corp is
$12, about 55.4% above its last closing price of $5.35.
This summary was machine generated February 1 at 14:58 GMT. All
figures in US dollars unless otherwise stated